In today’s session Zoetis Inc (ZTS) registered an unusually high (501) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious ZTS increase. With 501 contracts traded and 134 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: ZTS161118C00049500 closed last at: $1.2 or 9.1% up. About 3.10 million shares traded hands or 2.65% up from the average. Zoetis Inc (NYSE:ZTS) has risen 8.59% since March 30, 2016 and is uptrending. It has outperformed by 5.57% the S&P500.
Zoetis Inc (NYSE:ZTS) Ratings Coverage
Out of 11 analysts covering Zoetis Inc (NYSE:ZTS), 8 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 73% are positive. Zoetis Inc has been the topic of 20 analyst reports since July 24, 2015 according to StockzIntelligence Inc. On Friday, September 11 the stock rating was upgraded by BMO Capital Markets to “Outperform”. The rating was maintained by Jefferies on Tuesday, June 14 with “Buy”. On Thursday, August 4 the stock rating was maintained by Citigroup with “Neutral”. Stifel Nicolaus initiated the shares of ZTS in a report on Wednesday, June 1 with “Buy” rating. The rating was downgraded by Zacks on Monday, September 7 to “Hold”. Goldman Sachs downgraded Zoetis Inc (NYSE:ZTS) on Friday, May 6 to “Sell” rating. Barclays Capital maintained Zoetis Inc (NYSE:ZTS) on Thursday, August 4 with “Equal-Weight” rating. The stock has “Buy” rating given by Zacks on Thursday, September 17. The firm has “Buy” rating given on Thursday, September 29 by Bank of America. As per Thursday, February 4, the company rating was initiated by Credit Suisse.
According to Zacks Investment Research, “Zoetis Inc. is an animal health company. The company discovers, develops, manufactures and markets veterinary vaccines and medicines with a focus on both farm and companion animals. It primarily operates in the United States, Europe, Africa, the Middle East, Canada, Latin America, and the Asia Pacific. Zoetis Inc. is based in Madison, United States.”
Insitutional Activity: The institutional sentiment increased to 1.08 in 2016 Q2. Its up 0.15, from 0.93 in 2016Q1. The ratio improved, as 48 funds sold all Zoetis Inc shares owned while 212 reduced positions. 72 funds bought stakes while 210 increased positions. They now own 451.82 million shares or 1.32% less from 457.84 million shares in 2016Q1.
Williams Jones Limited Liability Company last reported 0% of its portfolio in the stock. Pioneer Invest Inc, a Massachusetts-based fund reported 3.08 million shares. Reliance Tru Of Delaware has 40,802 shares for 0.15% of their US portfolio. New Mexico Educational Retirement Board reported 53,175 shares or 0.11% of all its holdings. Loring Wolcott Coolidge Fiduciary Advsr Limited Liability Partnership Ma accumulated 0% or 3,415 shares. Babson Cap Management Limited Liability Corp last reported 115,827 shares in the company. Northeast Consultants owns 9,500 shares or 0.2% of their US portfolio. Reynders Mcveigh Cap Mngmt Limited Liability last reported 11,141 shares in the company. Moreover, M&T State Bank Corp has 0.12% invested in Zoetis Inc (NYSE:ZTS) for 380,235 shares. Lazard Asset Management Limited Liability Corp holds 2.2% of its portfolio in Zoetis Inc (NYSE:ZTS) for 20.19M shares. Aperio Grp Limited Liability Corp, a California-based fund reported 157,917 shares. Kbc Grp Inc Nv accumulated 0.12% or 173,727 shares. Paloma Prns Co last reported 0.01% of its portfolio in the stock. Cubist Systematic Strategies Lc has 3,191 shares for 0.01% of their US portfolio. Airain Ltd holds 0.09% or 31,918 shares in its portfolio.
Insider Transactions: Since May 9, 2016, the stock had 1 insider purchase, and 3 sales for $786.61 million net activity. Another trade for 32,097 shares valued at $1.64M was sold by Chen Heidi C.. Fenton Andrew sold $710,838 worth of stock or 13,870 shares. $102,680 worth of Zoetis Inc (NYSE:ZTS) was bought by MCCALLISTER MICHAEL B on Tuesday, September 6. $784.37 million worth of Zoetis Inc (NYSE:ZTS) shares were sold by Pershing Square Capital Management – L.P..
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company has a market cap of $23.19 billion. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish , and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It has a 37.19 P/E ratio. It operates through two divisions: the United States and International.
ZTS Company Profile
Zoetis Inc., incorporated on July 25, 2012, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Firm operates through two divisions: the United States and International. Within each of these divisions, the Company offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.
More news for Zoetis Inc (NYSE:ZTS) were recently published by: Forbes.com, which released: “Ex-Dividend Reminder: Ambev, KB Home and Zoetis” on October 28, 2016. Forbes.com‘s article titled: “December 16th Options Now Available For Zoetis (ZTS)” and published on October 24, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.